Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma
- PMID: 28316084
- DOI: 10.1002/ijc.30697
Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16-driven oropharyngeal squamous cell carcinoma
Abstract
To determine the sensitivity and specificity of HPV16 serology as diagnostic marker for HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), 214 HNSCC patients from Germany and Italy with fresh-frozen tumor tissues and sera collected before treatment were included in this study. Hundred and twenty cancer cases were from the oropharynx and 94 were from head and neck cancer regions outside the oropharynx (45 oral cavity, 12 hypopharynx and 35 larynx). Serum antibodies to early (E1, E2, E6 and E7) and late (L1) HPV16 proteins were analyzed by multiplex serology and were compared to tumor HPV RNA status as the gold standard. A tumor was defined as HPV-driven in the presence of HPV16 DNA and HPV16 transformation-specific RNA transcript patterns (E6*I, E1∧ E4 and E1C). Of 120 OPSCC, 66 (55%) were HPV16-driven. HPV16 E6 seropositivity was the best predictor of HPV16-driven OPSCC (diagnostic accuracy 97% [95%CI 92-99%], Cohen's kappa 0.93 [95%CI 0.8-1.0]). Of the 66 HPV-driven OPSCC, 63 were HPV16 E6 seropositive, compared to only one (1.8%) among the 54 non-HPV-driven OPSCC, resulting in a sensitivity of 96% (95%CI 88-98) and a specificity of 98% (95%CI 90-100). Of 94 HNSCC outside the oropharynx, six (6%) were HPV16-driven. In these patients, HPV16 E6 seropositivity had lower sensitivity (50%, 95%CI 19-81), but was highly specific (100%, 95%CI 96-100). In conclusion, HPV16 E6 seropositivity appears to be a highly reliable diagnostic marker for HPV16-driven OPSCC with very high sensitivity and specificity, but might be less sensitive for HPV16-driven HNSCC outside the oropharynx.
Keywords: biomarker; diagnosis; early proteins; head and neck squamous cell carcinoma; human papillomavirus; oropharynx; serology.
© 2017 UICC.
Similar articles
-
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium.Ann Oncol. 2019 Aug 1;30(8):1335-1343. doi: 10.1093/annonc/mdz138. Ann Oncol. 2019. PMID: 31185496 Free PMC article.
-
Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.Cancer. 2017 Nov 15;123(22):4382-4390. doi: 10.1002/cncr.30966. Epub 2017 Sep 26. Cancer. 2017. PMID: 28950407 Free PMC article.
-
Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis.Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):683-9. doi: 10.1158/1055-9965.EPI-14-1217. Epub 2015 Jan 26. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 25623733 Free PMC article.
-
The interplay between HPV and host immunity in head and neck squamous cell carcinoma.Int J Cancer. 2014 Jun 15;134(12):2755-63. doi: 10.1002/ijc.28411. Epub 2013 Aug 29. Int J Cancer. 2014. PMID: 23913554 Review.
-
From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas.Cancer Treat Rev. 2016 Jan;42:24-9. doi: 10.1016/j.ctrv.2015.10.009. Epub 2015 Oct 31. Cancer Treat Rev. 2016. PMID: 26547133 Review.
Cited by
-
Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer.Biomedicines. 2024 Feb 10;12(2):415. doi: 10.3390/biomedicines12020415. Biomedicines. 2024. PMID: 38398017 Free PMC article. Review.
-
GroEL-A Versatile Chaperone for Engineering and a Plethora of Applications.Biomolecules. 2022 Apr 19;12(5):607. doi: 10.3390/biom12050607. Biomolecules. 2022. PMID: 35625535 Free PMC article. Review.
-
Blood-based screening for HPV-associated cancers.medRxiv [Preprint]. 2024 Feb 2:2024.01.04.24300841. doi: 10.1101/2024.01.04.24300841. medRxiv. 2024. PMID: 38328243 Free PMC article. Preprint.
-
Assessing the feasibility of a multimodal liquid biopsy for the diagnosis of HPV-associated oropharyngeal squamous cell carcinoma.Am J Clin Pathol. 2024 Jun 3;161(6):570-578. doi: 10.1093/ajcp/aqad185. Am J Clin Pathol. 2024. PMID: 38349613
-
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium.Ann Oncol. 2019 Aug 1;30(8):1335-1343. doi: 10.1093/annonc/mdz138. Ann Oncol. 2019. PMID: 31185496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources